Correction: Wang, F.; Multhoff, G. Repurposing Cannabidiol as a Potential Drug Candidate for Anti-Tumor Therapies. Biomolecules 2021, 11, 582
1
Radiation-Immuno Oncology Group, TranslaTUM—Central Institute for Translational Cancer Research, Klinikum rechts der Isar, TU München, Einsteinstr. 25, 81675 Munich, Germany
2
Department of Oncology, The Second Affiliated Hospital of Zunyi Medical University, Zunyi 563000, China
3
Department of Radiation Oncology, Klinikum rechts der Isar, TU München, 81675 Munich, Germany
*
Author to whom correspondence should be addressed.
Biomolecules 2023, 13(2), 225; https://doi.org/10.3390/biom13020225
Submission received: 16 January 2023
/
Accepted: 17 January 2023
/
Published: 24 January 2023
There was a misplaced reference in the original article in the first paragraph of Section 6 “Clinical Trials with CBD” [1]. By misplacing reference 138 in the original article, an inaccurate interpretation of the study was made.
The amendment is listed below, to which in addition, a sentence has been removed in order to maintain the paragraph’s readability:
“Due to its non-psychoactive characteristics, CBD is superior to other cannabinoids in clinical applications. A double-blind, placebo-controlled, randomized clinical phase I trial has been started to prove its safety and capability to relieve tumor-related adverse effects at a CBD concentration of 100 mg/mL, within a dose range of 50 mg to 600 mg per day, in 2 weeks [138].”
The authors apologize for any inconvenience caused and state that the conclusions of the original article have been unaffected. The original publication has been updated.
Reference
- Wang, F.; Multhoff, G. Repurposing Cannabidiol as a Potential Drug Candidate for Anti-Tumor Therapies. Biomolecules 2021, 11, 582. [Google Scholar] [CrossRef] [PubMed]
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
MDPI and ACS Style
Wang, F.; Multhoff, G. Correction: Wang, F.; Multhoff, G. Repurposing Cannabidiol as a Potential Drug Candidate for Anti-Tumor Therapies. Biomolecules 2021, 11, 582. Biomolecules 2023, 13, 225. https://doi.org/10.3390/biom13020225
AMA Style
Wang F, Multhoff G. Correction: Wang, F.; Multhoff, G. Repurposing Cannabidiol as a Potential Drug Candidate for Anti-Tumor Therapies. Biomolecules 2021, 11, 582. Biomolecules. 2023; 13(2):225. https://doi.org/10.3390/biom13020225
Chicago/Turabian StyleWang, Fei, and Gabriele Multhoff. 2023. "Correction: Wang, F.; Multhoff, G. Repurposing Cannabidiol as a Potential Drug Candidate for Anti-Tumor Therapies. Biomolecules 2021, 11, 582" Biomolecules 13, no. 2: 225. https://doi.org/10.3390/biom13020225
Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.
